{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:04:56Z","timestamp":1792757096789,"version":"4.5.0"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec id=\"ab-hbr260017-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by extracellular myocardial ATTR amyloid infiltration. Vutrisiran, an RNA interference therapeutic that suppresses hepatic TTR production, met its primary end point in the HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy) trial. Multiparametric cardiovascular magnetic resonance (CMR) imaging provides high-fidelity structural and functional assessment, including tissue characterization metrics, namely extracellular volume (ECV) mapping, that can track cardiac amyloid load.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260017-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze the association between treatment with vutrisiran and changes in cardiac structure, function, and amyloid burden by CMR imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260017-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a retrospective post hoc analysis of CMR data from participants in the UK HELIOS-B trial. This was a single-center study conducted at the UK National Amyloidosis Centre (NAC). The study population comprised participants from the HELIOS-B trial at the NAC who underwent CMR imaging at baseline and 1-, 2-, and 3-year time points as part of routine clinical care. Study data were analyzed March to April 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260017-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>CMR imaging during the HELIOS-B trial between April 2020 and August 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260017-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>CMR parameters of cardiac structure, volumetrics, function, and amyloid burden were assessed. Amyloid regression and progression were defined as absolute reductions and increases in ECV of 5% or greater, respectively. Analysis was blinded to treatment allocation. Changes in CMR parameters between baseline and follow-up were evaluated; a mixed-model analysis was used to assess treatment effect. Sensitivity analyses were conducted using the last observation carried forward.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260017-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 43 patients (mean [SD] age, 75.0 [5.7] years, 41 male [95.3%]) underwent baseline CMR imaging (21 [48.8%] received vutrisiran; 22 [51.2%] received placebo). Thirty-nine patients (21 received vutrisiran, 18 received placebo), 26 (14 received vutrisiran, 12 received placebo), and 17 (9 received vutrisiran, 8 received placebo) underwent 1-, 2-, and 3-year CMR imaging, respectively. Baseline parameters were comparable between groups. No patients received background tafamidis. Treatment with vutrisiran was associated with statistically significant and directionally favorable changes in biventricular ejection fractions (left ventricular ejection fraction least-squares mean difference, 19.18%; 95% CI, 11.76%-26.60%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001; right ventricular ejection fraction, 16.28%; 95% CI, 9.58%-22.97%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and stroke volumes (left ventricular stroke volume, 27.82 mL; 95% CI, 13.40-42.23 mL;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001; right ventricular stroke volume, 23.69 mL; 95% CI, 8.06-39.32 mL;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.003), as well as reductions in left ventricular mass (\u221223.58 g; 95% CI, \u221238.78 to \u22128.39 g;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.002) and ECV (\u22126.56%; 95% CI, \u221210.10% to \u22123.01%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). At 36 months, amyloid regression was observed in 2 of 9 patients (22%) taking vutrisiran, and no patients receiving placebo experienced regression. Conversely, 5 of 8 patients (63%) receiving placebo demonstrated progression vs 1 of 9 patients (11%) taking vutrisiran.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260017-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Results of this selected ATTR-CM cohort study show that treatment with vutrisiran was associated with favorable changes in parameters relating to cardiac structure, function, and amyloid burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.2812","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:00:20Z","timestamp":1786546820000},"page":"1001","source":"Crossref","is-referenced-by-count":1,"title":["Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI"],"prefix":"10.1001","volume":"11","author":[{"given":"Yousuf","family":"Razvi","sequence":"first","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awais","family":"Sheikh","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi K.","family":"Patel","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Achten","sequence":"additional","affiliation":[{"name":"Maastricht University CARIM School, Maastricht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Mansell","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez-Naharro","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Venneri","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Moon","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, St Bartholomew\u2019s Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vest","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bansilal","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Eraly","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Aldinc","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"hbr260017r1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu Rev Med"},{"issue":"1","key":"hbr260017r2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"46","key":"hbr260017r3","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1093\/eurheartj\/ehaf412","article-title":"Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance.","volume":"46","author":"Patel","year":"2025","journal-title":"Eur Heart J"},{"issue":"45","key":"hbr260017r4","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.","volume":"43","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"hbr260017r5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression.","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"hbr260017r6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis.","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"hbr260017r7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis.","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hbr260017r8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012135","article-title":"Effect of acoramidis on myocardial structure and function in transthyretin amyloid cardiomyopathy: insights from the Attribute-CM Cardiac Magnetic Resonance (CMR) substudy.","volume":"17","author":"Razvi","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"5","key":"hbr260017r9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jacc.2025.09.1512","article-title":"Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis.","volume":"87","author":"Claggett","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hbr260017r10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacc.2025.06.022","article-title":"Effects of vutrisiran on cardiac function and outcomes in patients with transthyretin amyloidosis with cardiomyopathy.","volume":"86","author":"Jering","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hbr260017r11","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1038\/s41591-025-03851-z","article-title":"Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial.","volume":"31","author":"Jering","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"hbr260017r12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/eurheartj\/ehaf667","article-title":"Transthyretin amyloid cardiomyopathy: from cause to novel treatments.","volume":"47","author":"Fontana","year":"2026","journal-title":"Eur Heart J"},{"issue":"23","key":"hbr260017r13","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy.","volume":"388","author":"Fontana","year":"2023","journal-title":"N Engl J Med"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2852859\/jamacardiology_razvi_2026_br_260017_1790870229.02143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:00:55Z","timestamp":1791990055000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2852859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.2812","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}